Zamarin D - Search Results

1

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D. Oseledchyk A, et al. Among authors: zamarin d. Oncotarget. 2018 Jun 19;9(47):28702-28716. doi: 10.18632/oncotarget.25614. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983890 Free PMC article.

2

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Holmgaard RB, et al. Among authors: zamarin d. J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10. J Exp Med. 2013. PMID: 23752227 Free PMC article.

3

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Zamarin D, et al. Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095. Sci Transl Med. 2014. PMID: 24598590 Free PMC article.

4

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T. Khalil DN, et al. Among authors: zamarin d. Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. Adv Cancer Res. 2015. PMID: 26216629 Review.

5

Immunotherapy of Melanoma.

Snyder A, Zamarin D, Wolchok JD. Snyder A, et al. Among authors: zamarin d. Prog Tumor Res. 2015;42:22-9. doi: 10.1159/000436998. Epub 2015 Sep 4. Prog Tumor Res. 2015. PMID: 26376963 Review.

6

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Holmgaard RB, et al. Among authors: zamarin d. Cell Rep. 2015 Oct 13;13(2):412-24. doi: 10.1016/j.celrep.2015.08.077. Epub 2015 Sep 24. Cell Rep. 2015. PMID: 26411680 Free PMC article.

7

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.

Zamarin D, Wolchok JD. Zamarin D, et al. Mol Ther Oncolytics. 2014 Dec 10;1:14004. doi: 10.1038/mto.2014.4. eCollection 2014. Mol Ther Oncolytics. 2014. PMID: 27119094 Free PMC article. Review.

8

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.

Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Holmgaard RB, et al. Among authors: zamarin d. EBioMedicine. 2016 Apr;6:50-58. doi: 10.1016/j.ebiom.2016.02.024. Epub 2016 Feb 13. EBioMedicine. 2016. PMID: 27211548 Free PMC article.

9

Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors.

Ricca J, Turkekul M, Barlas A, Yarilin D, Fujisawa S, Fan N, Brendel M, Zamarin D, Wolchok JD, Manova-Todorova K. Ricca J, et al. Among authors: zamarin d. Methods Mol Biol. 2017;1554:253-262. doi: 10.1007/978-1-4939-6759-9_18. Methods Mol Biol. 2017. PMID: 28185198 Free PMC article.

10

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Zamarin D, et al. Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340. Nat Commun. 2017. PMID: 28194010 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

137 results

Search Page